Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 7, 2008, Pages 1229-1236

  Santra, Saikat ^a   Baumann, Ulrich ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

fetoprotein; Hepatocellular carcinoma; Hereditary tyrosinaemia type 1; Liver transplantation; Nitisinone

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; ALPHA FETOPROTEIN; MALEYLACETATE REDUCTASE; NITISINONE; CYCLOHEXANONE DERIVATIVE; ENZYME INHIBITOR; NITROBENZOIC ACID DERIVATIVE;

CARDIOMYOPATHY; CHRONIC LIVER DISEASE; CORNEA LESION; DIET RESTRICTION; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; KIDNEY CALCIFICATION; KIDNEY TUBULE DISORDER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; TYROSINEMIA; CHILD; DRUG ANTAGONISM; LIVER DISEASE; LIVER TUMOR; MONITORING; PATHOPHYSIOLOGY;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; CARCINOMA, HEPATOCELLULAR; CHILD; CYCLOHEXANONES; ENZYME INHIBITORS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MONITORING, PHYSIOLOGIC; NITROBENZOATES; TYROSINEMIAS;

EID: 43049172048     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.7.1229     Document Type: Review

References (59)

1. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinaemia. Proc Natl Acad Sci USA 1977;74:4641-5
2. Heath SX, Gray RG, McKiernan P, et al. Mutation screening for tyrosinaemia type I. J Inherit Metab Dis 2002;25:523-4
3. Mitchell GA, Grompe M, Lambert M, Tanguay R. Hypertyrosinemia. In: Scriver CR, Beaudet AR, Sly WS, et al. editors, The metabolic and molecular bases of inherited disease. 8th edition. New York: McGraw-Hill; 2001. p. 1777-805
4. Pitkanen ST, Salo MK, Heikinheimo M. Hereditary tyrosinaemia type I: from basics to progress in treatment. Ann Med 2000;32:530-8
5. De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet 1990;47:302-7
6. Bergeron A, Jorquera R, Orejuela D, Tanguay RM. Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I. J Biol Chem 2006;281:5329-34
7. Kubo S, Sun M, Miyahara M, et al. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA 1998;95:9552-7
8. Jorquera P, Tanguay RM. Cyctin B-dependent kinase and caspase-I activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J 1999;13:2284-98
9. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001;10:1741-52
10. Luijerink MC, Jacobs SM, van Beurden EA, et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol 2003;39:901-9
11. Bird S, Miller NJ, Collins JE, Rice-Evans CA. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC. J Inherit Metab Dis 1995;18:123-6
12. Roth KS, Spencer PD, Higgins ES, Spencer RF. Effects of succinylacetone on methyl alpha-D-glucoside uptake by the rat renal tubule. Biochim Biophys Acta 1985;820:140-6
13. Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 1983;71:625-34
14. Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322:432-7
15. van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187-91
16. Castilloux J, Laberge AM, Martin SR, et al. "Silent" tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl. J Pediatr Gastroenterol Nutr 2007;44:375-7
17. Gibbs TC, Payan J, Brett EM, et al. Peripheral neuropathy as the presenting fearture of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. J Neurol Neurosurg Psychiatry 1993;56:1129-32
18. Baumann U, Preece MA, Green A, et al. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 2005;28:131-5
19. Arora N, Stamper O, Wright J, et al. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 2006;29:54-7
20. Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type I. Eur J Pediatr 1999;158(Suppl 2):S49-54
21. Lock EA, Ellis MK, Gaskin P, et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis 1998;21:498-506
22. Ellis MK, Whitfield AC, Gowans LA, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro4-methanesulfonylbenzoyl)-cyclohexance-1,3-dione. Toxicol Appl Pharmacol 1995;133:12-9
23. Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol 1996;141:439-47
24. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813-7
25. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000;4:805-14
26. Drug to treat rare pediatric liver disease. FDA Consum 2002;36:5
27. Kavana M, Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry 2003;42:10238-45
28. Hanauske-Abel HM, Popowicz A, Remorti H, et al. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. J Pediarr Gastroenterol Nutr 2002;35:73-8
29. Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology 2000;144:179-87
30. Hall MG, Wilks MF, Provan WM, et al. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol 2001;52:169-77
31. Holme E, Lindstedt S, Tyrosinaemia type I and NTBC (2-(2-nitro4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998;21:507-17
32. Joshi SN, Venugopalan P. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation. Ann Trop Paediatr 2004;24:259-65
33. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006;66:743-50
34. Grompe M, Lindstedt S, al-Dhalimy M, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995;10:453-60
35. Crone J, Moslinger D, Bodamer OA, et al. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I. Acta Paediatr 2003;92:625-8
36. Karam V. European Liver Transplant Registry (ELTR), update of June 2007. Available from: www.eltr.org
37. Perez-Cerda C, Merinero B, Sanz P, et al. Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inherit Metab Dis 1995;18:119-22
38. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in die chronic form of hereditary tyrosinemia. J Pediatr 1976;88:434-8
39. van Spronsen FJ, Bijleveld CM, van Maldegem BT Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoromethylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005;40:90-3
40. Koelink CJ, van Hasselt P, van der Ploeg A, et al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab 2006;89:310-5
41. McKiernan P, Baumann U, Preece MA, et al. Should we monitor lectin reactive alpha-fetoprotein in children with tyrosinaemia type I? J Inherit Metab Dis 2005;28:58
42. Baumann U, Duhme V, Auth MK, et al. Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 2006;43:77-82
43. Baumann U, Duhme V, Knerr I, et al. Lectin-reactive alpha-fetoprotein in tyrosinaemia type I. Klin Padiatr 2005;217:142-6
44. Pronicka E, Rowinska E, Bentkowski Z, et al. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC). J Inherit Metab Dis 1996;19:234-8
45. Andre N, Roquelaure B, Jubin V, Ovaert C. Successful treatment of severe cardiomyopathy with NTBC in 2 child with tyrosinaemia type I. J Inherit Metab Dis 2005;28:103-6
46. Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31:81-7
47. Ros J, Vilaseca MA, Lambruschini N, et al. NTBC as palliative treatment in chronic tyrosinaemia type I. J Inherit Metab Dis 1999;22:665-6
48. Lock EA, Gaskin P, Ellis MK, et al. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat. Toxicol Appl Pharmacol 1998;150:125-32
49. Lock EA, Gaskin P, Ellis M, et al. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury. Toxicol Appl Pharmacol 2006;215:9-16
50. Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol 2002;134:266-8
51. Gissen P, Preece NLA, Willshaw HA, McKiernan PJ. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J Inherit Metab Dis 2003;26:13-6
52. Paradis K. Tyrosinemia: the Quebec experience. Clin Invest Med 1996;19:311-6
53. Weigel JF, Janzen N, Plaffle RW, et al. Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia. J Inherit Metab Dis 2007;30:610
54. Johnson DW, Gerace R, Ranieri E, et al. Analysis of succinylacetone, as a Girard T derivative, in urine and dried bloodspots by flow injection electrospray ionization tandem mom spectrometry. Rapid Commun Mass Spectrom 2007;21:59-63
55. Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 2005;28:871-6
56. Grompe M, Overturf K, al-Dhalimy M, Finegold M. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. J Inherit Metab Dis 1998;21:518-31
57. Anikster Y, Nyhan WL, Gahl WA. NTBC and alkaptonuria. Am J Hum Genet 1998;63:920-1
58. Phornphutkul C, Introne WJ, Perry MB. et al. Natural history of alkaptonuria. N Engl J Med 2002;347:2111-21
59. Suwannarat P, O'Brien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005;54:719-28